tarceva
Tarceva (Erlotinib Hydrochloride) is a medication used to treat Non-Small-Cell Lung Carcinoma.
Erlotinib Hydrochloride · by Osi Pharms
Key facts
- Active ingredient
- Erlotinib Hydrochloride
- Form
- Tablet
- Strength
- Erlotinib Hydrochloride EQ 100MG Base **Federal Register Determination That Product was not Discontinued or Withdrawn for Safety or Effectiveness reasons** · Erlotinib Hydrochloride EQ 150MG Base **Federal Register Determination That Product was not Discontinued or Withdrawn for Safety or Effectiveness reasons** · Erlotinib Hydrochloride EQ 25MG Base **Federal Register Determination That Product was not Discontinued or Withdrawn for Safety or Effectiveness reasons**
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- non-small-cell lung carcinoma
- Manufacturer
- Osi Pharms
- FDA application
- NDA021743
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
Dosage forms
Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Tarceva treat?
- Tarceva (Erlotinib Hydrochloride) may be used to treat non-small-cell lung carcinoma, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- Is there a coupon or discount for Tarceva?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Tarceva. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Tarceva?
- Tarceva is marketed by Osi Pharms. You can see Osi Pharms's full profile, rating, and other products on pharmaranks.
- Is Tarceva a brand-name or generic drug?
- Tarceva is a brand-name product with the active ingredient Erlotinib Hydrochloride.
- Is Tarceva available over the counter?
- No. Tarceva is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Tarceva come in?
- Tarceva is currently marketed as tablet, per the FDA's National Drug Code Directory.
- Is Tarceva FDA-registered?
- Tarceva is on record with the U.S. FDA under application number NDA021743. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about ERLOTINIB HYDROCHLORIDE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 2,863 reports naming ERLOTINIB HYDROCHLORIDE — the active ingredient in Tarceva, and the FDA flagged 99% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- diarrhoea332 reports
- rash251 reports
- neoplasm malignant174 reports
- anaemia158 reports
- nausea157 reports
- dehydration140 reports
- decreased appetite138 reports
- fatigue138 reports
Read these as a signal, not a rate. A report does not mean ERLOTINIB HYDROCHLORIDE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
alymsys
Bevacizumab-Maly
avastin
Bevacizumab
emrelis
Telisotuzumab Vedotin-Tllv
gilotrif
Afatinib Dimaleate
hernexeos
Zongertinib
keytruda
Pembrolizumab
Compare Tarceva head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
tarceva
New